Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
6.89
Dollar change
-0.86
Percentage change
-11.10
%
Index- P/E- EPS (ttm)- Insider Own49.18% Shs Outstand37.47M Perf Week-23.10%
Market Cap258.17M Forward P/E- EPS next Y-2.73 Insider Trans5.13% Shs Float18.91M Perf Month-36.67%
Income- PEG- EPS next Q-0.76 Inst Own0.00% Short Float5.26% Perf Quarter-
Sales- P/S- EPS this Y85.68% Inst Trans- Short Ratio4.42 Perf Half Y-
Book/sh-3.62 P/B- EPS next Y4.79% ROA- Short Interest1.00M Perf Year-
Cash/sh7.24 P/C0.95 EPS next 5Y- ROE- 52W Range7.67 - 12.74 Perf YTD-33.17%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-45.92% Beta-
Dividend TTM- Quick Ratio4.04 Sales past 5Y3569.20% Gross Margin- 52W Low-10.17% ATR (14)0.82
Dividend Ex-Date- Current Ratio4.04 EPS Y/Y TTM- Oper. Margin- RSI (14)23.04 Volatility11.75% 8.19%
Employees236 Debt/Eq0.22 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.20
Option/ShortNo / Yes LT Debt/Eq0.21 EPS Q/Q- Payout- Rel Volume0.81 Prev Close7.75
Sales Surprise6.89% EPS Surprise0.00% Sales Q/Q- EarningsMar 28 BMO Avg Volume225.06K Price6.89
SMA20-30.82% SMA50-36.79% SMA200-36.79% Trades Volume182,010 Change-11.10%
Date Action Analyst Rating Change Price Target Change
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerFeb 13 '24Buy15.00800,00012,000,0001,739,175Feb 15 08:38 PM
Novo Holdings A/S10% OwnerFeb 09 '24Buy10.25100,0001,025,000100,000Feb 15 08:38 PM